[en] Before being able to react against infectious non-self antigens, the immune system has to be educated in the recognition and tolerance of neuroendocrine proteins and this critical process takes place only in the thymus. The development of the autoimmune diabetogenic response results from a thymus dysfunction in programming central self-tolerance to pancreatic insulin-secreting islet β cells, leading to the breakdown of immune homeostasis with an enrichment of islet β-cell reactive effector T cells and a deficiency of β-cell specific natural regulatory T cells (nTregs) in the peripheral T-lymphocyte repertoire. Insulin-like growth factor 2 (IGF-2) is the dominant member of the insulin family expressed during fetal life by the thymic epithelium under the control of the autoimmune regulator (AIRE) gene/protein. The very low degree of insulin gene transcription in normal murine and human thymus explains why the insulin protein is poorly tolerogenic as evidenced in many studies, including the failure of all clinical trials that have attempted immune tolerance to islet β cells via various methods of insulin administration. Based on the close homology and cross-tolerance between insulin, the primary T1D autoantigen, and IGF-2, the dominant self-antigen of the insulin family, a novel type of vaccination, so-called “negative/tolerogenic self-vaccination”, is currently being developed for prevention and cure of T1D. If this approach were found to be effective for reprogramming immunological tolerance in T1D, it could pave the way for the design of other self-vaccines against autoimmune endocrine diseases, as well as other organ-specific autoimmune diseases.
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE] DGTRE - Région wallonne. Direction générale des Technologies, de la Recherche et de l'Énergie [BE] UE - Union Européenne [BE]
Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965, 14:619-633.
Bottazzo G.F., Florin-Christensen A., Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974, 2:1279-1283.
Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., Rewers M., Eisenbarth G.S., Jensen J., Davidson H.W., Hutton J.C. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad U S A 2007, 104:17040-17045.
Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., Piganelli J.D., Barbour G., Bradley B., Crawford F., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010, 11:225-232.
Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Mao D., Yu L., Wegmann D.L., Hutton J.C., Elliott J.F., Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005, 435:224-228.
Gale E.A.M., Bingley P.J. Autoimmune type 1 diabetes. Immunoendocrinology in Health and Disease 2004, 417-438. Marcel Dekker Inc, New York. V. Geenen, G.P. Chrousos (Eds.).
Notkins A., Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001, 108:1247-1252.
Martin S., Wolf-Eichbaum D., Duinkerken G., Scherbaum W.A., Kolb H., Noordzij J.G., Roep B.O. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001, 345:1036-1040.
Roep B.O. The role of T cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 2003, 46:305-321.
Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
Herold K.C., Brooks-Worrell B., Palmer J., Dosch H.M., Peakman M., Gottlieb P., Reijonen H., Arif S., Spain L.M., Thompson C., et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009, 58:2588-2595.
Nerup J., Platz P., Andersen O.O., Christy M., Lyngsoe J., Poulsen J.E., Ryder L.P., Nielsen L.S., Thomsen M., Svejgaard A. HLA antigens and diabetes mellitus. Lancet 1974, 2:864-866.
Noble J.A., Valdes A.M., Cook M., Klitz W., Thomson G., Erlich H.A. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996, 59:1134-1148.
Lee K.H., Wücherpfennig K.W., Wiley D.C. Structure of a human insulin peptide/HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001, 2:501-507.
Nejentsev S., Howson J.M.M., Walker N.M., Szeszko J., Field S.F., Stevens H.E., Reynolds P., Hardy M., King E., Masters J., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
Bell G.I., Horita S., Karam J.H. A polymorphism locus near the insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984, 33:176-183.
Bennett S.T., Lucassen A.M., Gough S.C.L., Powell E.E., Undlien D.E., Pritchard L.E., Merriman M.E., Kawaguchi Y., Dronsfield M., Pociot F., et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995, 9:284-292.
Nistico L., Buzzetti R., Pritchard L.E., Van der Auwera B., Giovanni C., Bosi E., Martinez Larrad M.T., Serrano-Rios M., Chow C.C., Cockram C.S., et al. The CTLA4 region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 1996, 5:1075-1080.
Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla4. Science 1995, 270:985-988.
Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika C., Rostamkhani M., McMurray J., Meloni G.F., Lucarelli P., Pellechia M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat Genet 2004, 36:337-338.
Criswell L.A., Pfeiffer K.A., Lum R.F., Gonzales B., Novitzke J., Kern M., Moser K.L., Begovich A.B., Carlton V.E.H., Li W., et al. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 [620W] allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005, 76:561-571.
Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., Nika K., Tautz L., Tasken K., Cucca F., et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005, 37:1317-1319.
Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., Buckner J.H. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007, 179:4704-4710.
The Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
Qu H.P., Montpetit A., Ge B., Hudson T.J., Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007, 56:1174-1176.
McCann J.A., Xu Y.Q., Frechette R., Guazzarotti L., Polychronakos C. The insulin-like growth factor-II receptor gene is associated with type 1 diabetes: evidence of a maternal effect. J Clin Endocrinol Metab 2004, 89:5700-5706.
Bailey R., Cooper J.D., Zeitels L., Smyth D.J., Yang J.H.M., Walker N.M., Hyppönen E., Dunger D.B., Ramos Lopez E., Badenhoop K., et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007, 56:2616-2621.
Karvonen M., Viik-Kajander M., Moltchanova E., Libman I., LaPorte R., Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23:1516-1526.
Bodansky H.J., Staines A., Stephenson C., Haigh D., Cartwright R. Evidence for an environmental effect in the aetiology of insulin-dependent diabetes in a transmigratory population. Br Med J 1992, 304:1020-1022.
Serrano-Rios M., Goday A., Martinez L.T. Migrant populations and the incidence of type 1 diabetes mellitus: an overview of the literature with a focus on the Spanish-heritage countries in Latin America. Diabetes Metab Rev 1999, 15:113-132.
Patterson C.C., Dahlquist G.G., Gyürüs E., Green A., Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373:2027-2033. and the EURODIAB Study Group.
Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920.
Zinkernagel R.M. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001, 345:1331-1335.
Anderson M.S., Bluestone J.A. The NOD mouse. Ann Rev Immunol 2005, 23:447-485.
Jun H.S., Yoon J.W. The role of viruses in type 1 diabetes: two distinct cellular and molecular mechanisms of virus-induced diabetes in animals. Diabetologia 2001, 44:271-285.
Jaeckel E., Manns M., Von Herrath M. Viruses and diabetes. Ann N Y Acad Sci 2002, 958:7-25.
Hyöti H., Hiltunen M., Knip M., Laakonen M., Vähäsalo P., Karjalainen J., Koskela P., Roivanen M., Leinikki P., Hovi T. A prospective role of coxsackie B and enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 1995, 44:652-667.
Yoon J.W., Austin M., Onodera T., Notkins A.L. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979, 300:1173-1179.
Gamble D.R., Kinsley M.L., Fitzgerald M.G., Taylor K.W. Viral antibodies in diabetes mellitus. Br Med J 1969, 3:627-630.
Gamble D.R., Taylor K.W. Coxsackie B virus and diabetes. Br Med J 1973, 1:289-290.
Clements G.B., Galbraith D.N., Taylor K.W. Coxsackie B virus infection and onset of childhood diabetes. Lancet 1995, 346:221-223.
Andreoletti L., Hober D., Hober-Vandenberghe C., Belaich S., Vantyghem M.C., Lefebvre J., Wattre P. Detection of coxsackie B virus RNA sequences in whole blood samples from adult patients at the onset of type 1 diabetes mellitus. J Med Virol 1997, 52:121-127.
Chehadeh W., Kerr-Conte J., Patou F., Alm G., Lefebvre J., Wattre P., Hober D. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha-interferon synthesis in beta cells. J Virol 2000, 74:10153-10164.
Yin H., Berg A.K., Westman J., Hellerström C., Frisk G. Complete nucleotide sequence of a coxsackievirus B4 strain capable of establishing persistent infection in human pancreatic islet cells: effects on insulin release, proinsulin synthesis, and cell morphology. J Med Virol 2002, 68:544-547.
Yin H., Berg A.K., Tuvemo T., Frisk G. Enterovirus RNA is found in peripheral blood mononuclear cells in a majority of type 1 diabetic children at onset. Diabetes 2002, 51:1964-1971.
Horwitz M.S., Bradley L.M., Harbetson J., Krahl T., Lee J., Sarvetnick N. Diabetes induced by coxsackievirus: initiation by bystander damage and not molecular mimicry. Nat Med 1998, 4:781-785.
Richter W., Mertens T., Schoel B., Muir P., Ritzkowsky A., Scherbaum W.A., Boehm B.O. Sequence homology of the diabetes-associated autoantigen glutamate decarboxylase with coxsackie B4-2C protein and heat shock protein 60 mediates no molecular mimicry of autoantibodies. J Exp Med 1994, 180:721-726.
Christen U., Edelmann K.H., McGavern D.B., Wolfe T., Coon B., Teague M.K., Miller S.D., Oldstone M.B., von Herrath M.G. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest 2004, 114:1290-1298.
Honeyman M.C., Stone N.L., Falk B.A., Nepom G., Harrison L.C. Evidence for a molecular mimicry between human T-cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol 2010, 184:2204-2210.
Horwitz M.S., Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999, 169:241-253.
Flodström M., Maday A., Balakrishna D., Cleary M.M., Yoshimura A., Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002, 3:373-384.
Chehadeh W., Weill J., Vantyghem M.C., Alm G., Lefebvre J., Wattre P., Hober D. Increased levels of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis 2000, 181:1929-1939.
Field L.L., Bonnevie-Nielsen V., Pociot F., Lu S., Nielsen T.B., Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 2005, 54:1588-1591.
Smyth D.J., Cooper J.D., Bailey R., Field S., Burren O., Smink L.J., Guja C., Ionescu-Tirgoviste C., Widmer B., Dunger D.B., et al. A genome-wide association study of non-synonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006, 38:617-619.
Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
Geenen V., Kroemer G. Multiple ways to cellular immune tolerance. Immunol Today 1993, 14:573-575.
Martens H., Goxe B., Geenen V. The thymic repertoire of neuroendocrine-related self-antigens: physiological implications in T-cell life and death. Immunol Today 1996, 17:312-317.
Kyewski B., Klein L. A central role for central tolerance. Annu Rev Immunol 2006, 24:571-606.
Dion M.L., Bordi R., Zeidan J., Asaad R., Boulassel M.R., Routy J.P., Lederman M.M., Sekaly R.P., Cheynier R. Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 2007, 109:2912-2920.
Castermans E., Baron F., Willems E., Schaaf-Lafontaine N., Meuris N., Gothot A., Vanbellinghen J.F., Herens C., Seidel L., Geenen V., et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008, 93:240-247.
Morrhaye G., Kermani H., Legros J.J., Baron F., Beguin Y., Moutschen M., Cheynier R., Martens H.J., Geenen V. Impact of growth hormone (GH) deficiency and GH replacement upon thymus function in adult patients. PLoS ONE 2009, 4:e5668.
Klein L., Hinterberger M., Wirnsberger G., Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009, 9:833-844.
von Boehmer H. Central tolerance: essential for preventing autoimmune disease?. Eur J Immunol 2009, 39:2313-2316.
Ashton-Rickardt P.G., Bandeira A., Delaney J.R., Van Kaer L., Pircher H.P., Zinkernagel R.M., Tonegawa S. Evidence for a differential avidity model of T cell selection in the thymus. Cell 1994, 76:651-663.
Vanneste Y., Ntodou Thome A., Vandersmissen E., Charlet C., Franchimont D., Martens H., Lhiaubet A.M., Schimpff R.M., Rostene W., Geenen V. Identification of neurotensin-related peptides in human thymic epithelial cell membranes and relationship with major histocompatibility complex class I molecules. J Neuroimmunol 1997, 76:161-166.
Geenen V., Brilot F., Hansenne I., Martens H. Thymus and T-cells. Encyclopedia of Neuroscience on CD-ROM 2003, Elsevier, New York. edn 3. G. Adelman, B.H. Smith (Eds.).
Derbinski J., Gäbler J., Brors B., Tierling S., Jonnakuty S., Hergenhahn M., Peltonen L., Walter J., Kyewski B. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005, 202:33-45.
Hansenne I., Renard-Charlet C., Greimers R., Geenen V. Dendritic cell differentiation and tolerance to insulin-related peptides in Igf2-deficient mice. J Immunol 2006, 176:4651-4657.
Burnet F.M. A reassessment of the forbidden clone hypothesis of autoimmune diseases. Aust J Exp Biol Med 1973, 50:1-9.
Robert F., Martens H., Cormann N., Benhida A., Schoenen J., Geenen V. The recognition of hypothalamo-neurohypophysial functions by developing T cells. Dev Immunol 1992, 2:131-140.
Kishimoto H., Sprent J. A defect in central tolerance in NOD mice. Nat Immunol 2001, 2:1025-1031.
Zucchelli S., Holler P., Yamagata T., Roy M., Benoist C., Mathis D. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 2005, 22:385-396.
Kecha-Kamoun O., Achour I., Martens H., Collette J., Lefebvre P.J., Greiner D.L., Geenen V. Thymic expression of insulin-related genes in an animal model of type 1 diabetes. Diab Metab Res Rev 2001, 17:146-152.
Geenen V., Lefebvre P.J. The intrathymic expression of insulin-related genes: implications in physiopathology and prevention of type 1 diabetes. Diab Metab Rev 1998, 14:95-103.
Chentoufi A.A., Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance. Diabetes 2002, 51:1383-1390.
Thebault-Baumont K., Dubois-Laforgue D., Krief P., Briand J.P., Halbout P., Vallon-Geoffroy K., Morin J., Laloux V., Lehuen A., Carel J.C., et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003, 111:851-857.
Moriyama H., Abiru N., Paronen J., Sikora K., Liu E., Miao D., Devendra D., Beilke J., Gianani R., Gill R.G., Eisenbarth G.S. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003, 100:10376-10381.
Vafiadis P., Bennett S.T., Todd J.A., Nadeau J., Grabs R., Goodyer C.G., Wickramasinghe S., Colle E., Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997, 15:289-292.
Pugliese A., Zeller M., Fernandez A, Zalcberg L.J., Bartlett R.J., Ricordi C., Pietropaolo M., Eisenbarth G.S., Bennett S.T., Patel D.D. The insulin gene is transcribed in human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997, 15:293-297.
Fan Y., Rudert W.A., Grupillo M., He J., Sisino G., Trucco M. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 2009, 28:2812-2824.
Nagamine K., Peterson P., Scott H.S., Kudoh J., Minoshima S., Heino M., Krohn K.J.E., Lalioti M.D., Mullis P.E., Antonorakis S.E., et al. Positional cloning of the APECED gene. Nat Genet 1997, 17:393-398.
Finnish-German APECED Consortium An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997, 17:399-403.
Heino M., Peterson P., Silanpää N., Guerin S., Wu L., Anderson G., Scott H.S., Antonorakis S.E., Kudoh J., Shimizu N., et al. RNA and protein expression of the murine autoimmune regulator gene (Aire) in normal. RelB-deficient and in NOD mouse. Eur J Immunol 2000, 30:1884-1893.
Ramsey C., Winqvist O., Puhakka, Halonen M., Moro A., Kämpe O., Eskelin P., Pelto-Huikko M., Peltonen L. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 2002, 11:397-409.
Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., von Boehmer H., Bronson R., Dierich A., Benoist C., Mathis D. Projection of an immunological self-shadow in the thymus by the Aire protein. Science 2002, 298:1395-1401.
Hubert F.X., Kinkel S.A., Crewther P.E., Cannon P.Z.F., Webster K.E., Link M., Uibo R., O'Bryan M.K., Meager A., Forehan S.P., et al. Aire-deficient C57BL/6 mice mimicking the common human 13-base pair deletion mutation present with only a mild autoimmune phenotype. J Immunol 2009, 182:3902-3918.
Niki S., Oshikawa K., Mouri Y., Hirota F., Matsushima A., Yano M., Han M., Bando Y., Izumi K., Matsumoto M., et al. Alteration of intra-pancreatic target-organ specificity by abrogation of Aire in NOD mice. J Clin Invest 2006, 116:1292-1301.
Brilot F., Chehadeh W., Charlet-Renard C., Martens H., Geenen V., Hober D. Persistent infection of human thymic epithelial cells by coxsackievirus B4. J Virol 2002, 76:5260-5265.
Brilot F., Geenen V., Hober D., Stoddart C. Coxsackievirus B4 infection of human fetal thymus cells. J Virol 2004, 78:9854-9861.
Jaïdane H., Gharbi J., Lobert P.E., Lucas B., Hiar R., M'Hadheb M.B., Brilot F., Geenen V., Aouni M., Hober D. Prolonged viral detection in blood and lymphoid tissues from coxsackievirus B4 E2 orally-inoculated mice. Microbiol Immunol 2006, 50:971-974.
Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
Keymeulen B., Vandemeulebroecke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7:622-632.
Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2006, 11:569-576.
Isaacs J. T cell immunomodulation-the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007, 7:418-425.
Tian J., Kaufman D.L. Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 2009, 58:1939-1946.
Agardh C.D., Lynch K.F., Palmer M., Link K., Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomized dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009, 52:1363-1368.
Ludvigsson J., Faresjö M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2009, 359:1909-1920.
Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006, 116:1371-1381.
Tateishi K., Taranova O., Liang G., D'Alessio A.C., Zhang Y. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008, 283:31601-31607.